Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach

At Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach, clinical trials focus on neoplasms across a broad range of cancers, with work centered on testing new treatment combinations, improving disease control, and extending survival in patients with hard-to-treat malignancies.

• Studies in lymphoma and large B-cell lymphoma are evaluating whether newer immune-based approaches can improve outcomes compared with current standard therapies.
• Research in ovarian cancer and endometrial cancer is examining treatment effectiveness for advanced, recurrent, and platinum-resistant disease.
• Trials in breast cancer are exploring targeted and endocrine-based strategies for ER-positive, HER2-negative and triple-negative disease.
• Several studies in melanoma are assessing approaches to reduce recurrence and improve long-term disease control after surgery.
• Work in acute myeloid leukemia and myelodysplastic syndrome is focused on patients with relapsed or high-risk disease who need better treatment options.
• Additional research includes advanced prostate cancer, with an emphasis on targeted therapy for castration-resistant disease.

Overall, the site supports a wide oncology portfolio aimed at improving survival, lowering the risk of recurrence, and refining care for patients with complex cancers.

The site conducts focused studies in blood cancers, especially diffuse large B-cell lymphoma, mantle cell lymphoma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, with the goal of improving responses in patients whose disease has returned or is difficult to control.

• Trials in lymphoma are testing whether adding novel immune therapies can strengthen standard treatment and delay progression.
• Research in acute myeloid leukemia is examining new combinations for patients who have not responded well to previous therapy.
• Studies in myelodysplastic syndrome are designed to better understand anti-leukemic activity in high-risk disease.
• Clinical work at the clinic in Kielce also includes evaluation of treatment benefit in newly diagnosed aggressive large B-cell lymphoma.

These investigations aim to improve progression-free survival, deepen remission, and expand options for people with challenging hematologic cancers.

In gynecologic oncology, the research portfolio includes ovarian cancer and endometrial cancer, reflecting a strong interest in advanced and recurrent disease where better systemic treatment is needed.

• Studies in ovarian, fallopian tube, and primary peritoneal carcinoma are evaluating whether new treatment strategies can improve control after prior therapy.
• Trials in endometrial cancer are assessing whether adding immunotherapy can reduce the risk of recurrence after surgery.
• Research in advanced epithelial ovarian cancer is focused on strengthening first-line treatment effectiveness.
• Work on advanced or recurrent endometrial cancer is examining maintenance approaches for longer disease control.

The overall purpose is to test more effective ways to treat gynecologic cancers, with attention to survival, recurrence prevention, and durable disease management.

The site is actively studying breast cancer, including ER-positive, HER2-negative advanced disease and triple-negative breast cancer, with trials designed to improve treatment response in both hormone-driven and more aggressive tumor types.

• Research in ER-positive, HER2-negative advanced breast cancer is exploring new endocrine-based options for tumors that resist earlier treatment.
• Studies in triple-negative breast cancer are testing whether novel combinations can improve outcomes in locally advanced or metastatic disease.
• These trials also aim to better define which patients may benefit most from targeted treatment strategies.

This area of research is centered on improving treatment effectiveness and extending disease control in difficult-to-treat breast cancers.

The oncology program at this site includes trials in melanoma and skin cancer, with a particular focus on reducing recurrence risk after surgery and improving immune-based treatment benefit.

• Studies in high-risk resected melanoma are evaluating whether newer therapies can help prevent the cancer from returning.
• Additional research in melanoma is looking at ways to strengthen long-term disease-free outcomes.
• Trials in skin cancer are assessing the safety and effectiveness of emerging cancer treatments in both adults and children.

These efforts aim to improve recurrence-free survival and support more effective post-surgical care for patients with melanoma and related skin malignancies.

Research in prostate cancer at this site focuses on castration-resistant disease, particularly cases identified by PSMA PET, with the goal of improving disease control when standard hormone approaches are no longer sufficient.

• Trials are evaluating whether targeted radioligand-based treatment can improve PSA response and clinical benefit.
• Some studies also examine whether combining targeted therapy with androgen pathway inhibitors may offer added value.

This research supports the development of more precise treatment options for advanced prostate cancer.